Valuation: PREDILIFE

Market Cap 3.99M 4.46M 3.69M 3.34M 6.25M 424M 6.35M 44.37M 17.55M 222M 16.73M 16.37M 702M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.76M 9.8M 8.11M 7.34M 13.74M 932M 13.96M 97.56M 38.59M 488M 36.78M 36M 1.54B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-8.91%
1 week+8.24%
Current month-8.91%
1 month-10.24%
3 months-3.16%
6 months-69.54%
Current year-69.44%
1 week 0.85
Extreme 0.85
1.01
1 month 0.85
Extreme 0.85
1.02
Current year 0.85
Extreme 0.85
4
1 year 0.85
Extreme 0.85
4
3 years 0.85
Extreme 0.85
24
5 years 0.85
Extreme 0.85
24
10 years 0.85
Extreme 0.85
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-8.91%+8.24%-70.70%-84.54% 4.46M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.15%-0.15%+9.63%+77.21% 54.57B
-0.08%+1.28%+9.40%+101.21% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.96%+14.60%+59.47%+48.58% 26.5B
Average -1.78%+4.03%+36.46%+125.02% 38.33B
Weighted average by Cap. -0.79%+2.27%+45.65%+148.41%

Financials

2024 2025
Net sales 493K 552K 456K 413K 773K 52.48M 786K 5.49M 2.17M 27.45M 2.07M 2.03M 86.9M 836K 935K 773K 700K 1.31M 88.93M 1.33M 9.31M 3.68M 46.51M 3.51M 3.43M 147M
Net income -4.26M -4.77M -3.95M -3.57M -6.69M -454M -6.8M -47.48M -18.78M -237M -17.9M -17.52M -751M -3.93M -4.4M -3.64M -3.3M -6.17M -419M -6.27M -43.8M -17.33M -219M -16.51M -16.16M -693M
Net Debt 3.54M 3.96M 3.27M 2.96M 5.55M 376M 5.64M 39.39M 15.58M 197M 14.85M 14.53M 623M 4.78M 5.34M 4.42M 4M 7.49M 508M 7.61M 53.19M 21.04M 266M 20.05M 19.62M 842M
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
27/10/26 €0.9200 -8.91% 134
26/10/26 €1.010 0.00% 0
23/10/26 €1.010 +18.82% 2,110
22/10/26 €0.8500 0.00% 0
21/10/26 €0.8500 0.00% 0

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock